Researchers evaluated the change in the inclination to use apps related to physical activity and fitness between 2020 and 2023.
Sucunamostat by Scohia Pharma for Metabolic Dysfunction-Associated Steatohepatitis (MASH): Likelihood of Approval
Share this article GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug